查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830990

子宫颈癌治疗市场

Cervical Cancer Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

子宫颈癌治疗市场预计将从 2024 年的 102.6 亿美元增加到 2031 年的 149.1 亿美元，2025 年至 2031 年的预计复合年增长率为 5.7%。

市场洞察与分析师观点：子宫颈癌治疗市场的预测可以帮助利害关係人制定成长策略。

子宫颈癌是指发生在子宫颈细胞（即连接阴道的子宫下段）的癌症。 90% 的子宫颈癌病例由 HPV 感染引起，可透过抹片筛检确诊。子宫颈癌发生率的上升和 HPV 感染的增加是推动子宫颈癌治疗市场成长的主要因素。然而，对诊断和治疗方案缺乏认识对市场成长构成了挑战。子宫颈癌治疗市场的趋势包括加强对子宫颈癌诊断和治疗的研发。

成长动力与挑战：子宫颈癌发生率上升推动市场成长在全球范围内，癌症正成为死亡的主要原因。根据世界卫生组织 (WHO) 的数据，2019 年，癌症是 183 个国家 70 岁以下人口的首要死因，也是其他 123 个国家的第四大死因。此外，WHO 2021 年 3 月的资料显示，2020 年有近 1,000 万人死于各种癌症。由于全球女性子宫颈癌发生率不断上升，子宫颈癌治疗市场经历了显着成长。 WHO 报告称，子宫颈癌每年夺走超过 27 万名女性的生命，由于诊断较晚，低收入国家的死亡率更高。

子宫颈癌发生率的上升给全球医疗体系带来了巨大压力。国际癌症研究机构 (IARC) 估计，到 2040 年，全球新增癌症病例将达到约 2,750 万，并导致约 1.63 亿人死亡。生活方式的改变、吸烟、体力活动减少以及不确定的健康和环境条件等因素预计将在未来几年加剧癌症负担。因此，控制和预防全球癌症病例的上升至关重要。

导致子宫颈癌高发病率和高死亡率的因素包括民众、医疗服务提供者和政策制定者缺乏认知；优质医疗服务和子宫颈筛检计画的机会有限；以及转诊系统不完善。在已开发国家，由于细胞学筛检机会的改善和早期子宫颈病变的及时治疗，子宫颈癌的发生率和死亡率都有所下降。在中低收入国家 (LMIC) 进行以人群为基础的子宫颈筛检并提高其接受度对于降低子宫颈癌死亡率至关重要。提高对早期性行为、多名男性性伴侣、HPV 8、9 和 10 型相关风险、早期足月妊娠、长期口服避孕药使用以及 HIV 感染等风险因素的认知，可以鼓励人们参与筛检计画。提高对子宫颈癌症状（包括经间期出血、停经后出血、性交后出血、恶臭阴道分泌物和下腹痛）的认知，可以促使女性及早就医。因此，民众对子宫颈癌认知的缺乏是子宫颈癌治疗市场成长的一大障碍。

策略洞察报告细分和范围：細項分析：市场按类型分为鳞状细胞癌、腺鳞状细胞癌和腺癌。鳞状细胞癌在2022年子宫颈癌治疗市场中占据较大份额，预计2022年至2030年期间的复合年增长率将更高。按产品划分，市场分为外科手术、放射疗法、化疗、免疫疗法和治疗性疫苗，预计到2030年外科手术将保持相当大的份额。就最终用户而言，市场细分为医院、家庭护理、癌症中心和其他，其中医院在2022年占据最大份额。

区域分析：子宫颈癌治疗市场报告涵盖北美、欧洲、亚太地区、中东和非洲以及南美和中美等地区。 2022 年，北美占据子宫颈癌治疗市场的最大份额，其中美国占有相当大的份额。正在进行的研发活动、政府和私营部门的财政支持、IT 和製药公司之间的合作以及神经系统疾病发病率的上升是美国市场成长的主要驱动力。此外，预计政府旨在改进检测程序的措施将在预测期内使市场受益。越来越多地采用与罕见疾病相关的法规可能会为市场成长创造机会，例如美国癌症协会 (ACS) 于 2020 年 9 月修订了子宫颈癌筛检指南。

子宫颈癌治疗市场报告范围：产业发展与未来机会：子宫颈癌治疗市场的分析涉及识别和评估产业关键参与者。主要市场参与者的一些措施包括：

2024年1月，辉瑞公司和Genmab A/S宣布，美国食品药物管理局（FDA）已接受其补充生物製品许可申请（sBLA），以转换TIVDAK（tisotumab vedotin-tftv）的批准，用于治疗一线治疗后病情进展的复发性或转移性子宫颈癌患者。该申请已被授予优先审查资格，处方药使用者付费法（PDUFA）的目标截止日期为2024年5月9日。 2023年9月，广州誉衡生物科技股份有限公司（GloriaBio）宣布，全人源抗PD-1单株抗体Zimberelimab注射液（YuTuo，GLS-010）获得中国国家药品监督管理局（NMPA）的上市许可。此註射可作为复发性或转移性子宫颈癌 (R/M CC) 患者的单药疗法，这使得 Zimberelimab 成为全球第三个获准用于治疗子宫颈癌的免疫检查点抑制剂 (ICI) 抗体，也是中国首个获准的抗体。竞争格局与重点公司：子宫颈癌治疗市场报告中介绍的重点公司包括罗氏公司 (F.Hoffmann-La Roche Ltd)、默克夏普 (Merck Sharp)、Dohme Corp.、葛兰素史克公司 (GlaxoSmithKline plc.)、基因泰克公司 (Genentech Inc.)、安进公司 (GlaxoSmithKline plc.)、基因泰克公司 (Genentech Inc.)、安进公司 (Amgenx Inc.) Inc. (Pfizer Inc.) 和阿斯特捷利康 (AstraZeneca)。这些公司专注于扩大产品供应，以满足日益增长的全球需求。他们的国际影响力使他们能够服务广泛的客户群，从而扩大其市场覆盖范围。

目录

第一章：简介

第 2 章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：子宫颈癌治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：子宫颈癌治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：子宫颈癌治疗市场－全球市场分析

  • 子宫颈癌治疗—全球市场概览
  • 子宫颈癌治疗－全球市场及2030年预测

第七章：子宫颈癌治疗市场-收入分析-按类型，2020-2030

  • 概述
  • 腺癌
  • 腺鳞癌
  • 鳞状细胞癌

第 8 章：子宫颈癌治疗市场 - 收入分析 - 按产品，2020-2030 年

  • 概述
  • 加德西/加德西9
  • 希瑞适
  • 阿瓦斯汀
  • 可瑞达
  • 其他的

第九章：子宫颈癌治疗市场-收入分析-按配销通路，2020-2030年

  • 概述
  • 医院药房
  • 零售药局
  • 网路药局

第 10 章：子宫颈癌治疗市场 - 收入分析，2020-2030 年 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：子宫颈癌治疗市场 - 主要公司简介

  • F. Hoffmann-La Roche Ltd
  • Merck Sharp and Dohme Corp.
  • GlaxoSmithKline plc.
  • Genentech, Inc.
  • Amgen Inc.
  • Advaxis, Inc.
  • Biocon
  • Allergan, Inc
  • Pfizer Inc
  • AstraZeneca

第 14 章：附录

简介目录
Product Code: TIPRE00004058

The cervical cancer treatment market is expected to increase from US$ 10.26 billion in 2024 to US$ 14.91 billion by 2031, with a projected CAGR of 5.7% from 2025 to 2031.

Market Insights and Analyst Perspective:The forecast for the cervical cancer treatment market can assist stakeholders in formulating their growth strategies.

Cervical cancer is defined as cancer that develops in the cervix cells, which is the lower section of the uterus connecting to the vagina. In 90% of cases, cervical cancers are caused by HPV infections and are identified through smear screening. The rising incidence of cervical cancer and the increase in HPV infections are the primary factors propelling the growth of the cervical cancer treatment market. However, the lack of awareness regarding diagnosis and treatment options poses a challenge to market growth. Trends in the cervical cancer treatment market include heightened R&D efforts for cervical cancer diagnostics and therapeutics.

Growth Drivers and Challenges:Rising Incidence of Cervical Cancer Drives Market Growth

Globally, cancer is becoming a leading cause of death. According to the World Health Organization (WHO), cancer was the leading cause of death for individuals under 70 in 183 countries, and the fourth leading cause in 123 other nations in 2019. Additionally, WHO data from March 2021 indicated that nearly 10 million deaths in 2020 were due to various cancers. The cervical cancer treatment market has experienced significant growth, attributed to the increasing incidence of cervical cancer among women worldwide. The WHO reports that cervical cancer claims the lives of over 270,000 women annually, with higher mortality rates in low-income countries due to late-stage diagnosis.

The rising incidence of cervical cancer is placing a strain on healthcare systems globally. The International Agency for Research on Cancer (IARC) estimates that the global burden of new cancer cases will reach approximately 27.5 million, leading to around 163 million deaths by 2040. Factors such as lifestyle changes, smoking, decreased physical activity, and uncertain health and environmental conditions are expected to exacerbate the cancer burden in the coming years. Therefore, it is crucial to control and prevent the rising number of cancer cases worldwide.

Factors contributing to the high incidence and mortality rates of cervical cancer include a lack of awareness among populations, healthcare providers, and policymakers; limited access to quality healthcare services and cervical screening programs; and inadequate referral systems. In developed countries, cervical cancer incidence and mortality have decreased due to improved access to cytological screening and prompt treatment of early cervical lesions. Implementing population-based cervical screening and enhancing its acceptance in low- and middle-income countries (LMICs) is vital for reducing cervical cancer mortality. Increasing awareness of risk factors such as early sexual activity, multiple male sexual partners, the risks associated with HPV types 8, 9, and 10, early full-term pregnancies, prolonged oral contraceptive use, and HIV infections may encourage participation in screening programs. Improved awareness of cervical cancer symptoms, including intermenstrual bleeding, postmenopausal bleeding, post-coital bleeding, foul vaginal discharge, and lower abdominal pain, could prompt women to seek early medical attention. Thus, the lack of awareness about cervical cancer among populations is a significant barrier to the growth of the cervical cancer treatment market.

Strategic Insights

Report Segmentation and Scope:Segmental Analysis:The market is categorized by type into squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. The squamous cell carcinoma segment held a larger share of the cervical cancer treatment market in 2022 and is expected to exhibit a higher CAGR from 2022 to 2030. By product, the market is divided into surgery, radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines, with the surgery segment anticipated to maintain a significant share by 2030. In terms of end users, the market is segmented into hospitals, homecare, cancer centers, and others, with hospitals holding the largest share in 2022.

Regional Analysis:The cervical cancer treatment market report covers regions including North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America accounted for the largest share of the cervical cancer treatment market in 2022, with the US holding a significant portion. Ongoing R&D activities, government and private sector financial support, collaborations between IT and pharmaceutical companies, and the rising incidence of neurological diseases are key drivers of market growth in the US. Additionally, government initiatives aimed at improving testing procedures are expected to benefit the market during the forecast period. The increasing adoption of regulations related to rare diseases is likely to create opportunities for market growth, such as the American Cancer Society (ACS) revising cervical cancer screening guidelines in September 2020.

Cervical Cancer Treatment Market Report Scope

Industry Developments and Future Opportunities:The analysis of the cervical cancer treatment market involves identifying and assessing key players in the industry. Some initiatives by major market players include:

In January 2024, Pfizer Inc. and Genmab A/S announced that the US Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) to convert TIVDAK's (tisotumab vedotin-tftv) approval for treating patients with recurrent or metastatic cervical cancer whose disease progresses after first-line therapy. The application has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 9, 2024.

In September 2023, Guangzhou Gloria Biosciences (GloriaBio) announced that Zimberelimab injection (YuTuo, GLS-010), a fully human anti-PD-1 monoclonal antibody, received marketing approval from the China National Medical Products Administration (NMPA). This injection can be used as a monotherapy for patients with recurrent or metastatic cervical cancer (R/M CC), making zimberelimab the third immune checkpoint inhibitor (ICI) antibody approved globally for cervical cancer treatment and the first authorized in China.

Competitive Landscape and Key Companies:Key companies profiled in the cervical cancer treatment market report include F.Hoffmann-La Roche Ltd, Merck Sharp, Dohme Corp., GlaxoSmithKline plc., Genentech Inc., Amgen Inc., Advaxis Inc., Biocon, Allergan Inc., Pfizer Inc., and AstraZeneca. These companies are focused on expanding their product offerings to meet the growing global demand. Their international presence enables them to serve a wide customer base, thereby enhancing their market reach.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Cervical Cancer Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Cervical Cancer Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Cervical Cancer Treatment Market - Global Market Analysis

  • 6.1 Cervical Cancer Treatment - Global Market Overview
  • 6.2 Cervical Cancer Treatment - Global Market and Forecast to 2030

7. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Type, 2020-2030

  • 7.1 Overview
  • 7.2 Adenocarcinoma
  • 7.3 Adenosquamous carcinoma
  • 7.4 Squamous cell carcinoma

8. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Product, 2020-2030

  • 8.1 Overview
  • 8.2 Gardasil/Gardasil 9
  • 8.3 Cervarix
  • 8.4 Avastin
  • 8.5 Keytruda
  • 8.6 Others

9. Cervical Cancer Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10. Cervical Cancer Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Cervical Cancer Treatment Market Overview
    • 10.1.2 North America Cervical Cancer Treatment Market Revenue and Forecasts to 2030
    • 10.1.3 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Type
    • 10.1.4 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Product
    • 10.1.5 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Cervical Cancer Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Cervical Cancer Treatment Market
        • 10.1.6.1.1 United States Cervical Cancer Treatment Market, by Type
        • 10.1.6.1.2 United States Cervical Cancer Treatment Market, by Product
        • 10.1.6.1.3 United States Cervical Cancer Treatment Market, by Distribution Channel
      • 10.1.6.2 Canada Cervical Cancer Treatment Market
        • 10.1.6.2.1 Canada Cervical Cancer Treatment Market, by Type
        • 10.1.6.2.2 Canada Cervical Cancer Treatment Market, by Product
        • 10.1.6.2.3 Canada Cervical Cancer Treatment Market, by Distribution Channel
      • 10.1.6.3 Mexico Cervical Cancer Treatment Market
        • 10.1.6.3.1 Mexico Cervical Cancer Treatment Market, by Type
        • 10.1.6.3.2 Mexico Cervical Cancer Treatment Market, by Product
        • 10.1.6.3.3 Mexico Cervical Cancer Treatment Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Cervical Cancer Treatment Market - Key Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Merck Sharp and Dohme Corp.
  • 13.3 GlaxoSmithKline plc.
  • 13.4 Genentech, Inc.
  • 13.5 Amgen Inc.
  • 13.6 Advaxis, Inc.
  • 13.7 Biocon
  • 13.8 Allergan, Inc
  • 13.9 Pfizer Inc
  • 13.10 AstraZeneca

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud